RxDoctor Payments Data

Vanessa Johnson

Hematology & Oncology · Durham, NCNPI 1326047549

Payments from drug & device makers

$45,386in general payments, 2019–2025

Across 640 payments — averaging $70.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$20K
  • Daiichi Sankyo Inc.$15K
  • Johnson & Johnson$1K
  • Genentech USA, Inc.$681
  • AstraZeneca$666
  • Merck$531
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$10,84894%
  • Education$2492%
  • Other$4664%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis46$20,202
Daiichi Sankyo Inc.17$14,750
Johnson & Johnson(2 entities)67$1,083
Genentech USA, Inc.47$681
AstraZeneca(2 entities)37$666
Merck33$531
Pfizer31$516
Bayer19$506
Seagen Inc.16$385
Bristol Myers Squibb18$357
Astellas Pharma US Inc18$341
Sanofi21$339
Gilead16$335
Incyte Corporation19$327
E.r. Squibb & Sons, L.L.C.16$306
Amgen18$290
Ipsen Biopharmaceuticals, Inc10$257
Eisai Inc.14$251
Lilly USA, LLC16$244
AbbVie13$241
Pharmacyclics LLC, An Abbvie Company11$221
Exelixis Inc.10$185
Rigel Pharmaceuticals, Inc.15$181
Takeda Pharmaceuticals U.S.A., Inc.7$161
GSK6$133
Jazz Pharmaceuticals Inc.9$132
Epizyme, Inc.7$115
Karyopharm Therapeutics Inc.7$112
ADC Therapeutics America, Inc.5$110
Flowonix Medical Incorporated1$93
Blueprint Medicines Corporation3$89
Array Biopharma Inc5$83
Regeneron Healthcare Solutions, Inc.3$79
EMD Serono, Inc.4$78
Pharmaessentia USA Corporation4$77
Sun Pharmaceutical Industries Inc.4$75
Pharmacosmos Therapeutics Inc.3$73
Heron Therapeutics, Inc.5$69
Sobi, Inc4$68
AMAG Pharmaceuticals, Inc.4$59
AVEO Pharmaceuticals, Inc.3$55
Acrotech Biopharma Inc.2$53
Taiho Oncology, Inc.2$49
Morphosys, US Inc.3$44
Verastem, Inc.2$37
Stemline Therapeutics Inc.2$30
Myriad Genetic Laboratories, Inc.2$30
Myovant Sciences Inc.1$27
Geron Corporation1$27
Mirati Therapeutics, Inc.1$24
Beigene USA, Inc.2$23
Advanced Accelerator Applications1$23
Coherus Oncology, Inc.1$22
Agios Pharmaceuticals, Inc.1$22
Kyowa Kirin, Inc.1$21
CTI Biopharma Corp.1$20
Foundation Medicine, Inc.1$19
Fortovia Therapeutics, Inc.1$17
Boehringer Ingelheim1$17
Clovis Oncology, Inc.1$15

How this compares

$45,386 in reported general payments places this provider in the 65th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,118,220
Medicare patients
384
Services billed
63,882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide12$209,282
XareltoRivaroxaban56$70,177
EliquisApixaban77$67,858
Imatinib Mesylate12$25,497
Exemestane87$16,905
OxycontinOxycodone Hcl11$9,579
Letrozole78$2,529
Anastrozole57$1,160
Tamoxifen Citrate30$936
Hydroxyurea42$804
Omeprazole47$767
Celecoxib27$672
Prochlorperazine Maleate32$597
Famotidine37$519
Gabapentin41$497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$357$209,28212 claims
Johnson & JohnsonXarelto$1,083$70,17756 claims
PfizerEliquis$516$67,85877 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →